HIV感染者肠道菌群的研究进展

Gut microbiota in HIV infection

艾滋病病毒(HIV)感染者的肠道菌群与一般人群相比有显著差异,抗反转录病毒治疗(ART)虽然能控制外周血中病毒载量,但无法逆转肠道菌群的变化。菌群紊乱与菌群移位与系统性炎症反应和异常的免疫激活密切相关,也影响HIV感染者的免疫重建和疾病进展。近年来的研究已发现菌群发挥作用的几个代谢通路,在肠道菌群的干预方面也进行了大量尝试。肠道菌群有望成为接下来HIV感染治疗的新靶点。

Gut microbiota of HIV-infected individuals harbor reproducible differences compared to healthy individuals.Antiretroviral therapy(ART)can suppress viral replication in plasma,but cannot reverse the alteration of gut microbiota.Microbiota dysbiosis and translocation during HIV infection correlate with persistence of immune activation and systemic inflammation,and influence immune reconstitution and clinical outcome.Recently,studies have revealed several possible metabolic pathways and trials have evaluated the effects of administering probiotics and prebiotics.Gut microbiota may be a new target in the treatment of HIV infection.